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Abstract The choice of serum for supplementation of
media for T cell assays and in particular, Elispot has been a
major challenge for assay performance, standardization,
optimization, and reproducibility. The Assay Working
Group of the Cancer Vaccine Consortium (CVC-CRI) has
recently identiWed the choice of serum to be the leading
cause for variability and suboptimal performance in large
international Elispot proWciency panels. Therefore, a serum
task force was initiated to compare the performance of
commercially available serum-free media to laboratories’
own medium/serum combinations. The objective of this
project was to investigate whether a serum-free medium
exists that performs as well as lab-own serum/media com-
binations with regard to antigen-speciWc responses and
background reactivity in Elispot. In this way, a straight-
forward solution could be provided to address the serum
challenge. Eleven laboratories tested peripheral blood
mononuclear cells (PBMC) from four donors for their
reactivity against two peptide pools, following their own
Standard Operating Procedure (SOP). Each laboratory
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performed  Wve simultaneous experiments with the same
SOP, the only diVerence between the experiments was the
medium used. The Wve media were lab-own serum-supple-
mented medium, AIM-V, CTL, Optmizer, and X-Vivo. The
serum task force results demonstrate compellingly that
serum-free media perform as well as qualiWed medium/
serum combinations, independent of the applied SOP.
Recovery and viability of cells are largely unaVected by
serum-free conditions even after overnight resting. Further-
more, one serum-free medium was identiWed that appears to
enhance antigen-speciWc IFN-secretion.
Keywords Elispot · Serum · Immune monitoring · 
Harmonization
Introduction
Immune monitoring is gaining an increasingly important
role in the developmental pipeline of immuno-therapeutical
vaccines including patient assessment for early immune
responses after vaccination [1]. New immune monitoring
techniques are constantly introduced, and known tech-
niques are adapted and further developed to meet the
demands of “exploring it all” [2, 3]. Nevertheless, a large
focus has been placed on the evaluation of T cell responses
with well-established assays like Elispot, intracellular cyto-
kine staining (ICS) and HLA-peptide multimer staining.
Elispot has earned its place as an excellent screening tool
due to its outstanding sensitivity and robustness, allowing
the detection of antigen-speciWc T cells in frequencies even
as low as 0.001% [4]. For patient assessment, many transla-
tional and clinical laboratories optimize and standardize
their Elispot protocol, which will be eventually exposed to
qualiWcation and validation procedures [5–7]. Since no gold
standard exists for this bioassay, participation in speciW-
cally designed proWciency panels is a prerequisite for
checking assay performance and provides a point of com-
parison to other laboratories testing the same samples for
the same reactivity, following their lab-own protocol [8, 9].
In 2005, the CVC-CRI addressed this need by initiating a
proWciency panel program for Elispot, followed by pro-
grams for ICS and HLA-peptide multimer staining [10, 11].
The program goal is to provide an external quality assur-
ance program and to harmonize the assay by identifying
crucial protocol variables that critically inXuence assay per-
formance. This oVers an elegant solution for assay optimi-
zation without imposing one standardized protocol on
individual laboratories. As a results of the Wrst two Elispot
proWciency panels, initial harmonization guidelines for Eli-
spot [10] were developed. These guidelines included the
need for laboratories to pretest their serum for optimal sig-
nal to noise ratio. In fact, the choice of serum was singled
out as the leading cause for sub-optimal Elispot perfor-
mance and variability in the Wrst two panels, as it was in
follow-up panels ([10], Janetzki unpublished).
While the inXuence of serum on T cell reactivity is
known to T cell immunologists, there are very few pub-
lished reports that address this issue in context of immune
monitoring [6,  12,  13]. Other reports focus on optimal
medium conditions for obtaining well-matured or clinical
grade dendritic cells [14–17], identifying serum-free condi-
tions with various supplements as an optimal choice. Inter-
estingly, Martunizzi et al. [13] found AIM-V serum-free
medium supplemented with low doses of IL-7 to perform
better in Elispot compared to own, human serum-supple-
mented media.
Moreover, it is a “known” secret that batches from the
same manufacturer or even the same serum can diVer
widely in performance due to non-speciWc activation of T
cells or suppression of antigen-speciWc responses. Thus,
many laboratories pretest multiple sera in order to identify
one suitable batch. Once such serum has been identiWed,
laboratories typically purchase the entire lot, in order to
guarantee the same performance for long-term studies.
However, these laboratories are still aVected by the serum’s
shelf life.
In order to address the diYculties posed by the serum
used in Elispot assays, the CVC-CRI Assay Working group
formed a serum task force with 11 consistently high per-
forming laboratories from the CVC panel as well as other
collaborating organizations (CHAVI, C-IMT-CIP, HVTN,
and IAVI). The objective of this project was to determine
whether a serum-free medium exists that performs equally
well in Elispot compared with serum-supplemented media
from diVerent laboratories, independent of serum type or
batch, and independent of the SOP applied. Here, we
describe the results of this project with speciWc attention to
antigen-speciWc spots and background reactivity as well as
recovery and viability after thawing and after overnight
resting. Spot sizes were also assessed in response to multi-
ple reports from serum task force members about obvious
medium-speciWc size diVerences observed during plate
evaluation.
Materials and methods
Serum task force participants
Eleven laboratories from the CVC and collaborating orga-
nizations (CHAVI, C-IMT-CIP, HVTN, and IAVI) partici-
pated. These labs represent academia, the biotech/
pharmaceutical sector, Elispot reagent manufacturer, and
the US Department of Defense. All labs were identiWed as
high-performing, experienced laboratories with ElispotCancer Immunol Immunother (2010) 59:609–618 611
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SOPs in place. All but one lab used serum-supplemented
media; one lab used AIM-V without serum supplementa-
tion, based on pretesting experiments.
PBMC and antigens
PBMC were obtained from the Immunology Quality
Assurance Center Laboratory (IQAC) of the Duke Human
Vaccine Institute, a division of the Duke University Medi-
cal Center in Durham NC. For this eVort, the IQAC labora-
tory collected PBMC samples from four healthy, HIV-1/2
sero-negative human volunteers via leukapheresis. Volun-
teers were recruited through IRB-approved methods.
Leukopaks were processed fresh in the IQAC laboratory,
within 4 h of collection. Separation of PBMC was accom-
plished by density gradient centrifugation. PBMC were
cryo-preserved in 10% DMSO and 90% heat-inactivated
FBS at 15 Million cells per vial using an automated con-
trolled rate freezer. Cryo-preserved PBMC were then
transferred and stored in two vapor phase LN2 freezers for
sample redundancy.
This study utilized the CEF and CMV pp65 control pep-
tide pools as antigen sources. While the CEF peptide pool,
obtained through the NIH AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH, con-
tains 32 8–11mers known to elicit CD8-restricted responses
[18], the CMV pp65 peptide pool, which was a generous
gift of the NIAID and Becton Dickinson, consists of 135
15mers overlapping by 11 amino acids and elicits CD8- and
CD4-restricted responses [19]. The above donors exhibited
diVerent response levels against both peptide pools, and
obtained PBMC were Elispot-tested at IQAC before ship-
ping. PBMC and peptides were shipped in liquid nitrogen
dry shippers using IATA approved methods. All procedures
were done in GCLP compliance.
Media
Each lab used their own medium/serum combination
based on previous pretesting results (Table 1). Further,
laboratories obtained the following media for compara-
tive analysis from their country-speciWc provider, thus
each lab used the same media, but likely from diVerent
production lots:
1. AIM-V therapeutic grade (Invitrogen);
2. CTL Wash and Test medium (Cellular Technology
Ltd.);
3. Optmizer T-cell expansion SFM (Invitrogen);
4. X-Vivo 15 (Lonza, Fisher ScientiWc).
No addition of any serum or other additives was allowed to
any of the serum-free media, for any protocol step.
Elispot assay
Elispot testing was performed as part of the fourth CVC-
CRI Elispot proWciency panel [10]. All labs participating in
the serum task force received Wve PBMC vials of each
donor and Wve vials of each peptide pool. In addition to the
same plate layout, laboratories had to follow minimal
requirements to allow comparability of results, which
included the total number of cells per well (200,000) and
the Wnal concentration of peptide per well (1 g/ml). Thus,
each donor had to be tested in six replicates for reactivity
against the CEF peptide pool, the CMV pp65 peptide pool,
and against the appropriate medium to assess background
reactivity, with an ex-vivo IFN Elispot assay. Laboratories
were otherwise allowed to use their own SOP including
materials, reagents, and equipment. Labs performed Wve
simultaneous experiments following the exact same SOP,
but appropriately exchanged the medium for all test condi-
tions including thawing, washing, resting and Wnal incuba-
tion of PBMC with antigen. Viability and recovery after
thawing and, if applicable after overnight resting, were
recorded for each medium. Final spot counts were uploaded
to the CVC data management web site. All plates were cen-
trally re-evaluated (ZellNet Consulting, Inc., Fort Lee, NJ,
USA). A response was deWned as spot counts ¸10 spots in
antigen-stimulated wells, at least 3£ above background
(cells plus medium alone).
Statistical analysis
The following parameters were calculated for the overall
panel and the individual participant’s performance, using
the central re-evaluation spot counts: the mean, standard
deviation, and coeYcient of variation (CV), the median,
minimum, and maximum spot counts for each donor and
Table 1 Medium/serum composition and serum provider among
serum task force laboratories
Lab location Lab medium/serum Serum provider
Canada RPMI/HuS Valley Biomedical
Germany IMDM/HuS cc-pro
Germany RPMI/HuS Lonza
Germany RPMI/HuS Cambrex
Germany AIM-V –
Sweden RPMI/FBS Gibco/Invitrogen
UK RPMI/FCS Sigma
USA RPMI/FCS Atlanta Biologics
USA NHS/HuS GemCell
USA RPMI/FBS GemBio
The Netherlands IMDM/FCS PAA Laboratories612 Cancer Immunol Immunother (2010) 59:609–618
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reagent and the medium only wells. Spot counts obtained
from the central re-evaluation were used instead of the lab-
oratories own spot counts in order to reduce operator-
dependent variability [20]. Box plots were used to illustrate
the distribution of spot counts with each serum type for a
given test condition. For the comparison of the spot counts
between laboratories that performed an overnight rest and
those that did not, a two sample Student’s t test was
applied.
To standardize the comparison of antigen-speciWc spot
counts for all seven positive responses across laboratories,
the ranks of the spot counts were used as opposed to the
actual spot count. Each laboratory generated 30 spot counts
for a given donor/reagent combination (6 replicates £ 5
media). These 30 spot counts from an individual laboratory
were ranked from 1 to 30, where 1 represented the smallest
spot count for that donor/reagent combination and 30 the
largest. As a result, the highest average ranking possible
would be 27.5 (in that case all 6 replicates of one medium
would have the largest spot counts among all 30
replicates = ranking 25–30, mean = 27.5), and the lowest
average ranking would be 3.5 (with all replicates having the
smallest spot counts compared with all other media =
ranking 1–6, mean 3.5). The same ranking method was also
applied for the comparison of spot sizes across media and
laboratories.
Results
Medium choice and antigen-speciWc responses
The goal of the serum task force was to identify if a serum-
free medium exists that performs equally well in Elispot
compared with serum-supplemented media. Among the
eight donor-antigen combinations, seven positive responses
could be detected, with all four donors being reactive to the
CEF peptide pool, and three donors being reactive to the
CMV pp65 peptide pool. Based on the reevaluation counts
and prospectively established positive response deWnition,
all laboratories detected all of these responses, when using
the AIM-V, Optmizer or X-Vivo medium. Two labs did not
detect the CEF response of Donor 1 with the CTL medium,
due to high background reactivity. Another lab missed the
CEF and CMV response of Donor 1 due to high back-
ground reactivity, but only when using lab-own medium.
Figure 1 demonstrates that there is no apparent diVerence in
spot numbers when either pretested lab-own medium/serum
or serum-free media were used. Further, it can be seen that
the Optmizer medium has a slightly higher mean and
median spot count for most donor/antigen combinations
compared to the other media. The average variability of
results among all participants for a given donor/antigen/
medium combination, expressed as the percent CV, was
39.4. In the light of diVerent SOPs used among all groups,
this comes at no surprise.
The results presented in Fig. 1 are averages across all
laboratories within a media type and do not necessarily reX-
ect the patterns occurring for an individual laboratory
across the diVerent media. To determine if the overall pat-
terns that existed when averaging across all laboratories
were consistently found within individual laboratories, a
comparison was made within each laboratory between the
spot counts found with each medium, using the ranking
method. Thus, the larger the spot counts obtained with one
medium, compared with all other media, the larger the
average ranking, and vice versa. The average ranking for
each medium and donor/antigen combination across all
laboratories is summarized in Table 2. The ranking results
conWrm that there was no apparent diVerence in perfor-
mance between the diVerent media and that there is a trend
to higher spot counts in experiments with Optmizer
medium. An interesting observation is that none of the
serum-free media has an overall lower ranking than
lab-own medium/serum combinations. This observation
extends to results separated by donor/antigen combination,
where only twice AIM-V has a slightly lower average rank-
ing than the lab-own media. Out of all possible lab and
medium/antigen combinations (not shown), 34.3% of the
largest average rankings were obtained with Optmizer
medium, whereas this was the case for only 8.6% with
lab-own medium.
Finally, all donor/antigen rankings were investigated for
media which have the largest average ranking for an indi-
vidual lab in at least 5 out of 7 possible donor–antigen com-
binations. Three labs were identiWed for which Optmizer
consistently produced higher spot counts, and one lab each
for AIM-V and CTL medium.
Overnight resting and antigen-speciWc responses
Overnight resting of thawed PBMC has been shown to pos-
itively inXuence spot counts [10, 12, 21] and is one of
the recommended Elispot harmonization guidelines. Since
serum is believed to be essential for prolonged culture of
PBMC, we investigated whether the use of serum-free
media would abrogate the positive eVect of a resting period
before Elispot testing. Pooling the spot counts of the seven
donor/antigen combinations with a positive response, a
comparison was made between the spot counts from labs
that did an overnight rest with those that did not. In Table 3,
the average spot counts from all replicates are displayed
stratiWed by medium type and overnight rest. A two sample
t test was used to compare the means of the two groups. For
each medium, the mean spot count from labs that did an
overnight rest was larger by more than 35 spots comparedCancer Immunol Immunother (2010) 59:609–618 613
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to the mean spot count from labs that did not do an over-
night rest. These diVerences were statistically signiWcant.
Hence, serum-free conditions did not abrogate the positive
eVect of overnight resting.
Medium choice and background reactivity
An important aspect of medium and serum suitability for
Elispot testing is the background reactivity it elicits.
Figure 2 demonstrates the background reactivity level for
all media across all donors. Except for a few well exceptions,
background reactivity was low for all media, with a trend
for the CTL medium having somewhat higher background
reactivity compared to all other media. As reported
earlier, the few missed responses (4 out of 385 positive
responses detectable in total by all labs, across all 5
media) were caused by high background reactivity with
lab-own medium (1 lab, 1 donor) or CTL medium (2 labs,
1 donor).
Medium choice and PBMC recovery and viability 
after thawing and overnight resting
Serum is believed to be an essential additive for optimal
recovery of PBMC during the thawing process as well as
for extended cell culture. On the other hand, even short
Fig. 1 Antigen-speciWc spot 
counts across all laboratories for 
each donor/antigen combination 
and medium. Box plots indicate 
the mean (triangle), median 
(horizontal line), 75th and 25th 
percentile (upper and lower box 
border) and minimum and 
maximum spot counts
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exposure to serum has been noted to inXuence background
reactivity or level of antigenic responses. Here the inXuence
of serum-free media on the recovery and viability of
cells after thawing and overnight resting was investi-
gated. Laboratories received Wve separate PBMC vials
from each donor batch, each of which had to be thawed
in and further handled with the appropriate medium
only. Eight out of 11 laboratories chose to rest cells
overnight prior to the assay. One lab was excluded from
this analysis due to the lack of serum supplementation
for the lab-own medium. Table 4 depicts the average
recovery and viability across all donors and laboratories,
sorted by medium with the highest value to the medium
with the lowest value. While the mean recovery after
thawing appears to be slightly higher with serum-supple-
mented media (on average by 1.3 Million, equaling 8.6%
of PBMC frozen per vial), this serum advantage disap-
pears after overnight resting, with a similar average cell
loss reported for all Wve media (2.9 Million), as demon-
strated in Table 5. Furthermore, only minimal diVerences
exist in the viability of cells after thawing or overnight
resting among all Wve media.
Medium choice and spot size
Upon plate evaluation, multiple laboratories reported obvi-
ous spot size diVerences between media. To investigate
whether spot size diVerences among plates from the same
laboratory exist, spot size data were recorded during central
reevaluation and further analyzed. Similar to the spot count
data, spot sizes were ranked within one lab for each repli-
cate and medium (30 rankings for 6 replicates £ 5 media),
hence the largest average ranking possible for one medium
Table 3 Overall spot counts 
stratiWed by medium and 
overnight resting
Medium Overnight 
rest
Mean Median Minimum 
spot count
Maximum 
spot count
P value
Lab own Yes 140.1 127 28 334 <0.001
No 101.6 93.5 38 219
AIM-V Yes 154.8 151 49 460 <0.001
No 107.0 96 28 244
CTL Yes 156.3 126 26 430 <0.001
No 118.7 103.5 11 264
Optmizer Yes 178.9 173.5 44 359 <0.001
No 114.8 102.5 29 320
X-Vivo Yes 166.7 154 39 360 <0.001
No 127.4 109.5 42 268
Table 2 Overall average spot count ranking of each medium for a
given donor (D)/antigen combination
Lab own AIM-V CTL Optmizer X-Vivo
D1/CMV 13.3 15.6 13.6 16.2 15.8
D1/CEF 14.0 13.1 15.9 15.8 15.3
D2/CEF 11.6 14.9 13.3 18.7 16.7
D3/CMV 11.4 12.0 13.7 19.0 18.1
D3/CEF 8.0 10.7 14.9 20.6 19.6
D4/CMV 14.5 12.5 14.1 17.4 17.1
D4/CEF 12.1 14.4 13.9 16.6 17.8
Overall 12.1 13.3 14.2 17.7 17.2
Fig. 2 Background reactivity of all media across all donors and labo-
ratories. Spot counts were obtained by testing PBMC with medium
only. Box plots indicate the mean (triangle), median (horizontal line),
75th and 25th percentile (upper and lower box border) and minimum
and maximum spot counts. The Wgure was clipped at spot counts of 26
per well for better graphical demonstration. For each medium type
there was the following number of wells that had a spot count above
26: Lab own 5 (spot counts: 105, 111, 123, 141, and 261), AIM-V 0,
CTL 8 (spot counts: 27, 28, 29, 30, 30, 33, 34, and 125), Optmizer 4
(spot counts: 32, 33, 44, and 60), and X-Vivo 4 (spot counts: 35, 42,
43, and 47)
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type would be 27.5 (with all 6 replicates of one medium
having the largest average spot sizes). The average ranking
positions for each medium per donor/antigen combination
are summarized in Table 6. In 73% of all possible medium/
donor/antigen combinations across all laboratories, the Opt-
mizer medium always produced highest average spot sizes,
and in 87% the Optmizer medium had either the largest or
second largest average spot sizes. In fact, in seven laborato-
ries, Optmizer use resulted in largest spots in at least Wve
out of the seven donor/antigen combinations. One lab had
the largest spot sizes with the CTL medium in Wve out of
seven combinations. The remaining labs had mixed results.
Figure 3 demonstrates two representative examples of the
spot sizes from each of the Wve media within one lab for a
speciWc donor/antigen combination.
Discussion
The presented study describes the eVorts of the serum task
force of the CVC-CRI to investigate whether a commer-
cially available serum-free medium could potentially be
used for replacement of serum-supplemented media in
IFN-Elispot testing. The study originated out of recent
observations in international proWciency panels that the
Table 5 DiVerences in cell recoveries (in Million) between thawing
and overnight resting
Three labs reported numbers for recovery after overnight rest that were
larger than the numbers reported for recovery at thawing. This
occurred for seven donor/medium combinations (AIM-V medium for
donor 1, lab-own and X-Vivo medium for donor 2, CTL and X-Vivo
medium for donor 3, and Optmizer and X-Vivo medium for donor 4).
These diVerences between recoveries after thawing versus overnight
rest were set to zero for these seven pairs of observations
Serum N Mean Median Minimum Maximum
X-Vivo 24 2.2 2.6 0 5.9
Optimizer 24 2.9 2.6 0 8.3
Lab 24 2.9 2.7 0 6.7
AIM-V 24 2.9 2.9 0 6.9
CTL 24 3.5 3.3 0 8.8
Table 4 PBMC recovery and 
viability stratiWed by medium
Variable Medium Mean Median Minimum Maximum
Recovery after thawing 
(in Million)
Lab own 11.7 12.3 4.9 15.2
Optmizer 11.0 10.9 6.3 16.2
CTL 10.5 10.4 5.3 16.2
X-Vivo 10.4 10.3 5.1 16.4
AIM-V 9.8 10.0 3.7 15.8
Recovery after overnight 
rest (in Million)
Lab own 9.7 10.8 3.3 15.1
X-Vivo 8.8 9.1 4.0 13.7
Optmizer 8.8 8.9 3.4 13.2
CTL 7.8 8.2 1.6 12.1
AIM-V 7.8 7.7 2.7 11
Viability after thawing 
(in percent)
Optmizer 90.4 94.7 61.5 99
Lab own 90.0 93.0 56 99
CTL 89.5 93.2 58 98.5
AIM-V 89.3 93.4 60.4 99
X-Vivo 88.7 89.2 62.8 99
Viability after overnight 
rest (in percent)
Lab own 91.5 93.6 72.1 98
X-Vivo 87.5 89.8 66.7 97
CTL 87.4 89.5 69.4 96.6
Optmizer 86.5 89.9 57.5 99
AIM-V 86.1 91.9 54.0 97
Rows are sorted by the mean 
with the media having the largest 
mean presented Wrst
Table 6 Overall spot size ranking of each medium for a given donor
(D)/antigen combination
Lab own AIM-V CTL Optmizer X-Vivo
D1/CMV 12.8 13.7 12.8 20.5 13.8
D1/CEF 11.6 15.4 12.9 21.4 12.6
D2/CEF 9.7 15.2 9.4 23.6 17.2
D3/CMV 11.9 15.5 10.9 22.4 13.4
D3/CEF 12.7 14.7 12.5 23.0 11.5
D4/CMV 14.9 13.2 9.9 21.8 15.6
D4/CEF 11.7 11.7 12.2 22.7 16.4
Overall 12.2 14.2 11.5 22.2 14.3616 Cancer Immunol Immunother (2010) 59:609–618
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choice of serum is the leading cause for variability and sub-
optimal assay performance, and the knowledge that each
serum batch is unique and can potentially introduce unpre-
dictable mitogenic, stimulatory, or suppressive factors to
assay conditions. A challenge for such study is the lack of a
gold standard. For this reason, the serum task force was ini-
tiated composed of high-performing groups which have
optimized their Elispot SOP for speciWc laboratory needs.
Hence, each group compared serum-free media to their own
medium-serum combination, and with their own unique
SOP. A generalized recommendation from the serum task
force is expected to hold up only if applicable across a con-
sortium of diVerent representative laboratories.
The excellent performance results of all serum-free
media in comparison with qualiWed medium/serum combi-
nations came at some surprise. The fact that no serum was
added at any step of the protocol was expected to nega-
tively inXuence recovery, viability and Wnal spot counts at
least for media which were not speciWcally developed for
Elispot use like the CTL Wash and Test media. However,
there were generally no apparent diVerences in spot counts
across all media in a given laboratory. Some variability was
observed, which could at least partially be accounted for by
the fact that each experiment was started with a separate
vial of donor PBMC, and variability could be introduced at
the thawing and cell-counting step. Most interestingly,
serum-free media were ranked higher in performance com-
pared to lab-own medium/serum combinations (Table 2).
These results conWrm earlier observations reported by
Martinuzzi [13].
An important optimization step for Elispot assays
using frozen PBMC is an overnight rest during which
many apoptotic cells get eliminated, resulting in a cell
population with more truly viable cells and Wnally
higher spot counts [10, 12, 21]. A critical Wnding from
this study was that overnight resting in serum-free media
does not lead to an increased cell loss in comparison to
serum-supplemented media. It needs to be noted that the
initial thawing process with serum-supplemented media
yielded slightly higher recoveries (on average close to
9%). This explains why slightly higher recoveries were
reported after overnight resting, considering the
observed similar cell loss rates as for serum-free media.
Together with the well maintained spot counts and low
background reactivity it can be reasonably recom-
mended to consider the use of serum-free media in an
IFN Elispot, without the addition of any serum at any
step of the protocol. Obviously, Standard Operating Pro-
cedures need to be optimized accordingly.
Serum-free media are highly standardized, and contain
identical components in every lot, but they do not share
mitogenic or suppressive factors which can potentially be
found in sera. Not only do serum-free media provide a
useful tool for Elispot optimization, standardization, and
harmonization, but their use saves time and reduces costs
since it prevents the need for pretesting of multiple serum
batches and purchase of entire serum lots.
One issue not addressed in this study is the use of serum
in freezing media. Short exposure to sub-optimal sera used
for freezing could have unwanted eVects as described ear-
lier. Consequently, the most desirable setup would be to use
serum-free freezing medium in combination with a serum-
free test medium. A few serum-free freezing media are
commercially available, but they have not yet been system-
atically investigated. To address this issue, a study is being
organized by the CIMT Immunoguiding Program (C-IMT-
CIP) in collaboration with the CVC-CRI, and results should
be expected by 2010.
An interesting observation made was that spot sizes
diVered remarkably, with Optmizer spots reported to be
signiWcantly larger than any of the other media spots. The
systematic analysis of spot sizes clearly conWrmed this
observation. It is important to stress that such changes in
spot appearances require an adjustment of reading parame-
ters for automated plate evaluation. Variation in the adjust-
ment capabilities among the various readers and software
Fig. 3 Spot appearance for each 
of the Wve media for the same 
donor/antigen and lab. Two rep-
resentative examples are 
displayed. a SpeciWc lab 
example for well B4 (Donor 1), b. 
b SpeciWc lab example for well 
E5 (Donor 3). In both examples, 
spot size diVerences 
can be recognized by eye
A
B
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versions available on the market also need to be considered,
further justifying the strategy for central reevaluation of all
serum task force plates.
In the majority of donor/antigen combinations Optmizer
produced considerably larger spots. Since all experiments
were done following the same SOP within a lab, the spot
size increase indicates the secretion of more cytokine over
time [4]. Given the identical experimental setup for all
media within a lab including the same antigen concentra-
tion and incubation time, the Optmizer medium must pro-
vide conditions, which enhance the signal strength [22].
Such a feature could be especially beneWcial for systems
which are known to produce very small spots as the perfo-
rin Elispot and, therefore, require extensive optimization
[23], provided that similar eVects are found for cyto/chemo-
kines other than IFN. For instance, the requirements to
obtain optimal responses by Th2, Th17 and T-reg cells may
be diVerent, and even IFN responses may vary depending
on speciWc requirements for diVerent ways of antigen pre-
sentation (e.g. for proteins or cell lysates). Examination of
the inXuence of such medium on ICS results could provide
further interesting results.
The results of the serum task force provide compel-
ling evidence that serum-free media can be a safe alter-
native for serum-supplemented media in IFN Elispot
testing of PBMC. It is important to stress that each par-
ticipant was a consistently high-performing laboratory
that worked with a SOP that was optimized for the spe-
ciWc medium/serum combination routinely used. Switch-
ing to a diVerent, serum-free medium will require
optimization for the new conditions introduced. Similar
conclusions have been made in the CIMT-CIP serum
study [24]. The availability of serum-free medium
choices provides an important tool for Elispot assay
standardization and harmonization.
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